What have we learned from pharmacokinetic and pharmacodynamic theories?

Clinical Infectious Diseases

Volumn 32, Issue , 2001, Pages S39-S46

  Schentag, Jerome J ^a   Gilliland, Kristin K ^a   Paladino, Joseph A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFACLOR; CEFMENOXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; CHRONOPHARMACOLOGY; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; LOWER RESPIRATORY TRACT INFECTION; OTITIS MEDIA; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; RESPIRATORY TRACT INFECTIONS;

EID: 0035867022     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/319375     Document Type: Review

References (32)

1. The pharmacodynamics of β-lactams
2. The pharmacodynamics of aminoglycosides
3. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: Comparison of murine and human pharmacokinetics
4. Comparative antibiotic dose effect relations at several dosing intervals in murine pneumonitis and thigh infection models
5. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
6. Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime
7. Pharmacodynamic interactions of antibiotics alone and in combination
8. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin
9. Antibiotic dosing issues in lower respiratory tract infections: Population-derived area under inhibitory curve is predictive of efficacy
10. A randomized, parallel group comparison of the bacterial eradication pharmacokinetics and pharmacodynamics of ciprofloxacin, vs azithromycin, vs clarithromycin in patients with chronic bronchitis
11. Efficacy of oral ciprofloxacin vs. Clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
12. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
13. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model
14. In vitro selection of resistance to four β-lactams and azithromycin in Streptococcus pneumoniae
15. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: Results of a 1992-93 Western Europe and USA collaborative surveillance study
16. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
17. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis
18. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
19. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
20. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin, and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus
21. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new "respiratory quinolones"
22. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin
23. Moxifloxacin: A comparison with other antimicrobial agents of in vitro activity against Streptococcus pneumoniae
24. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains
25. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae
26. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
27. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection
28. Moxifloxacin: A comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae
29. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man
30. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects
31. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration
32. Bactericidal properties of moxifloxacin and post-antibiotic effect